knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 19:01:38 - browse：3975

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： A new drug could help frostbite victims avoid its ravages

hotspot

WSS

Flagship Pioneering startup Sonata Therapeutics lays off 21

In diabetes hearing, Sanders takes on a new foe: food makers

Surprise medical billing ban raises prices elsewhere

CMS should re

Radiology is caught between AI's potential and concern for patients

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

focus

knowledge

focus

Trump demands the U.S. pay no more for drugs than other countries … again

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

After affirmative action ruling, medical educators look to 'holistic review'

Measles policy set amid Florida outbreak alarms vaccine proponents

Heart attack and stroke risk calculators need revising

Pregnancy discrimination could be enabled by AI

What does generative AI mean for health care? We asked experts

AI models in health care face new federal disclosure requirements

Walensky prepares to leave CDC — and Congress — behind

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

leisure time

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Secretariat’s lessons for human medicine

focus

hotspot

focus

knowledge